Developer docs
API playgroundTry for free, no card

Search company profiles

Rapidiagnostics

Full company profile

uuid003p3uw

Namestring
Rapidiagnostics
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Rapidiagnostics operates in the diagnostics space based on its company name and primary domain (rapidiagnostics.com), which suggest a focus on rapid diagnostic testing services—most plausibly in clinical, medical, veterinary, or life-sciences applications where shortened time-to-result is a competitive variable. The compound name "Rapid" + "diagnostics" strongly implies a speed-oriented positioning versus incumbent diagnostic workflows. No core products, services, technology stack, customer base, team composition, funding history, or financial details could be verified from the available public sources. The company presents no app presence, no API offering, no disclosed partnerships, no certifications or compliance registrations, and no patents or trademark filings.

The company's website (rapidiagnostics.com) currently displays only a loading/verification page with no substantive content. All structured data fields returned empty: headcount, GTM motion, revenue model, pricing details, office locations, customer segments, value proposition components, marketing and distribution channels, awards, investments, management team, regulatory actions, mergers and acquisitions, and restructuring or leadership changes are all unpopulated. No founding date, legal entity name, company type, domicile, operating geographies, or ownership structure could be confirmed. There is no evidence of a parent company, subsidiaries, or DBAs. Social media profiles and contact details are likewise absent.

Without verifiable operational data—including headcount, revenue model, pricing, go-to-market motion, customer segments, or any disclosed strategic actions—the investment thesis cannot be substantiated beyond the inferred positioning implied by the company name. This represents a material, total data gap requiring primary-source diligence (incorporation records, banking data, founder interviews, customer references) before any investment consideration or valuation work can proceed. The non-functional public-facing web presence is itself a diligence flag, suggesting either an early-stage entity, a dormant operation, or a company operating entirely behind a private veil.

Short descriptiontext

Rapidiagnostics appears to be a diagnostic testing company based on its name, suggesting speed-oriented testing services in a medical or clinical context. No substantive company information—products, customers, financials, team, or operations—could be verified from available sources due to a non-functional website and absence of public data.

Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersGuayaquil, Ecuador
HQ citystring
Guayaquil
HQ countrystring
Ecuador
HQ regionstring
Latin America
Markets served

Serves global market

Keyword5 values
rapid diagnostic tests, point-of-care testing, in-vitro diagnostics, clinical diagnostics, medical diagnostics
Industry1 code
PRIMARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
NAICS code1 code
  • Medical Laboratories621511
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Diagnostic Testing
Social media profiles2 records
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

No core offering description is available from the source data. The company's website at rapiddiagnostics.com returned only a verification/loading page and contained no substantive content describing what the company sells or the products/services it offers. Company name ("Rapidiagnostics") suggests a focus on rapid diagnostic products, but no supporting details are evidenced in the input.

Differentiator
Functional benefit
Problem solved
No data
Peers10 records
TypeBroad incumbent
Description

Hologic's Panther and Panther Fusion systems serve rapid molecular diagnostics in women's health and infectious disease, making it a comparable incumbent for the rapid diagnostics category.

TypeEmerging player
Description

Mesa Labs operates in specialty diagnostics and monitoring tools for clinical and industrial settings, providing a smaller-cap emerging-player comparable for a niche rapid diagnostics positioning.

TypeBroad incumbent
Description

Bio-Rad supplies clinical diagnostics instruments and reagents across immunology, molecular, and life science research, providing a comparable reference point for a diagnostics-focused company operating in regulated clinical markets.

TypeBroad incumbent
Description

Qiagen provides sample-prep and molecular testing solutions used in rapid and decentralized diagnostic workflows, making it a broad incumbent comparable on technology stack and customer segments.

TypeBroad incumbent
Description

BD offers BD MAX, BD Veritor, and other rapid diagnostic systems across infectious disease and point-of-care, comparable to a rapid diagnostics company both in product category and customer base.

TypeDirect peer
Description

Cepheid is a leading rapid molecular diagnostics company (GeneXpert platform), directly comparable to a 'rapid diagnostics' positioning: fast PCR-based results at the point of care for infectious disease, oncology, and critical care.

TypeBroad incumbent
Description

Roche operates one of the broadest diagnostics portfolios including rapid molecular (cobas Liat) and centralized systems; comparable as a large incumbent covering the same clinical customers a rapid diagnostics player would target.

TypeDirect peer
Description

QuidelOrtho manufactures rapid immunoassay and molecular diagnostics (e.g., Sofia, Triage), closely aligned with a rapid diagnostics brand in both product format (rapid cartridges) and end customers (hospitals, clinics, point-of-care).

TypeEmerging player
Description

GenMark developed the ePlex rapid multiplex molecular diagnostics system for syndromic testing; relevant as a focused emerging player whose rapid diagnostics platform overlaps directly with the category implied by Rapidiagnostics' name.

10Abbott Diagnostics
TypeBroad incumbent
Description

Abbott is a global diagnostics incumbent with a large rapid diagnostics franchise (Binax, ID NOW, Panbio), making it a broad comparable for any rapid diagnostics company targeting infectious disease and point-of-care.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses2 records

Each record includes

Headline, Details, Source

Key risks3 records

Each record includes

Headline, Details, Source

Key highlights1 record

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

No data
Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Rapidiagnostics

Diagnostic Testingrapidiagnostics.com

Rapidiagnostics appears to be a diagnostic testing company based on its name, suggesting speed-oriented testing services in a medical or clinical context. No substantive company information—products, customers, financials, team, or operations—could be verified from available sources due to a non-functional website and absence of public data.

What Rapidiagnostics does

Rapidiagnostics operates in the diagnostics space based on its company name and primary domain (rapidiagnostics.com), which suggest a focus on rapid diagnostic testing services—most plausibly in clinical, medical, veterinary, or life-sciences applications where shortened time-to-result is a competitive variable. The compound name "Rapid" + "diagnostics" strongly implies a speed-oriented positioning versus incumbent diagnostic workflows. No core products, services, technology stack, customer base, team composition, funding history, or financial details could be verified from the available public sources. The company presents no app presence, no API offering, no disclosed partnerships, no certifications or compliance registrations, and no patents or trademark filings.

The company's website (rapidiagnostics.com) currently displays only a loading/verification page with no substantive content. All structured data fields returned empty: headcount, GTM motion, revenue model, pricing details, office locations, customer segments, value proposition components, marketing and distribution channels, awards, investments, management team, regulatory actions, mergers and acquisitions, and restructuring or leadership changes are all unpopulated. No founding date, legal entity name, company type, domicile, operating geographies, or ownership structure could be confirmed. There is no evidence of a parent company, subsidiaries, or DBAs. Social media profiles and contact details are likewise absent.

Without verifiable operational data—including headcount, revenue model, pricing, go-to-market motion, customer segments, or any disclosed strategic actions—the investment thesis cannot be substantiated beyond the inferred positioning implied by the company name. This represents a material, total data gap requiring primary-source diligence (incorporation records, banking data, founder interviews, customer references) before any investment consideration or valuation work can proceed. The non-functional public-facing web presence is itself a diligence flag, suggesting either an early-stage entity, a dormant operation, or a company operating entirely behind a private veil.

Rapidiagnostics firmographics

Firmographics
Name
Rapidiagnostics
Website
https://rapidiagnostics.com
Company type
Private
Headcount range
51–100 employees
Short description
Rapidiagnostics appears to be a diagnostic testing company based on its name, suggesting speed-oriented testing services in a medical or clinical context. No substantive company information—products, customers, financials, team, or operations—could be verified from available sources due to a non-functional website and absence of public data.
Ownership category
akta.pro rank

Rapidiagnostics industry classification

Industry
Product category
Diagnostic Testing
NAICS
Medical Laboratories (621511)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics

Keywords

  • Rapid diagnostic tests
  • Point-of-care testing
  • In-vitro diagnostics
  • Clinical diagnostics
  • Medical diagnostics

Where Rapidiagnostics is headquartered

Location

Headquarters

HQ city
Guayaquil
HQ country
Ecuador
HQ region
Latin America

Markets served

Rapidiagnostics business model

Business model
GTM type
B2B
Offering type
Services

Rapidiagnostics product offering

Product offering

Core offering

No core offering description is available from the source data. The company's website at rapiddiagnostics.com returned only a verification/loading page and contained no substantive content describing what the company sells or the products/services it offers. Company name ("Rapidiagnostics") suggests a focus on rapid diagnostic products, but no supporting details are evidenced in the input.

Differentiator

Problem solved

Functional benefit

Rapidiagnostics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Rapidiagnostics competitors and assessment

Company assessment

Broad incumbents

  • Hologic: Hologic's Panther and Panther Fusion systems serve rapid molecular diagnostics in women's health and infectious disease, making it a comparable incumbent for the rapid diagnostics category.
  • Bio-Rad Laboratories: Bio-Rad supplies clinical diagnostics instruments and reagents across immunology, molecular, and life science research, providing a comparable reference point for a diagnostics-focused company operating in regulated clinical markets.
  • Qiagen: Qiagen provides sample-prep and molecular testing solutions used in rapid and decentralized diagnostic workflows, making it a broad incumbent comparable on technology stack and customer segments.
  • Becton Dickinson (BD): BD offers BD MAX, BD Veritor, and other rapid diagnostic systems across infectious disease and point-of-care, comparable to a rapid diagnostics company both in product category and customer base.
  • Roche Diagnostics: Roche operates one of the broadest diagnostics portfolios including rapid molecular (cobas Liat) and centralized systems; comparable as a large incumbent covering the same clinical customers a rapid diagnostics player would target.
  • Abbott Diagnostics: Abbott is a global diagnostics incumbent with a large rapid diagnostics franchise (Binax, ID NOW, Panbio), making it a broad comparable for any rapid diagnostics company targeting infectious disease and point-of-care.

Emerging players

  • Mesa Labs: Mesa Labs operates in specialty diagnostics and monitoring tools for clinical and industrial settings, providing a smaller-cap emerging-player comparable for a niche rapid diagnostics positioning.
  • GenMark Diagnostics (acquired by Roche): GenMark developed the ePlex rapid multiplex molecular diagnostics system for syndromic testing; relevant as a focused emerging player whose rapid diagnostics platform overlaps directly with the category implied by Rapidiagnostics' name.

Direct peers

  • Cepheid (Danaher): Cepheid is a leading rapid molecular diagnostics company (GeneXpert platform), directly comparable to a 'rapid diagnostics' positioning: fast PCR-based results at the point of care for infectious disease, oncology, and critical care.
  • QuidelOrtho: QuidelOrtho manufactures rapid immunoassay and molecular diagnostics (e.g., Sofia, Triage), closely aligned with a rapid diagnostics brand in both product format (rapid cartridges) and end customers (hospitals, clinics, point-of-care).

Market position

Strengths1 record

Weaknesses2 records

Key risks3 records

Key highlights1 record

Customer concentration

Rapidiagnostics social profiles

Digital presence

Rapidiagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Rapidiagnostics leadership team

Management profile

Number of profiles

Rapidiagnostics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Rapidiagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rapidiagnostics

What does Rapidiagnostics do?

No core offering description is available from the source data. The company's website at rapiddiagnostics.com returned only a verification/loading page and contained no substantive content describing what the company sells or the products/services it offers. Company name ("Rapidiagnostics") suggests a focus on rapid diagnostic products, but no supporting details are evidenced in the input.

When was Rapidiagnostics founded?

Rapidiagnostics was founded in -1. It employs 51 to 100 people.

Where is Rapidiagnostics based?

Rapidiagnostics is headquartered in Guayaquil, Ecuador, in the Latin America region.

Who are Rapidiagnostics's main competitors?

Broad incumbents on record are Hologic, Bio-Rad Laboratories, Qiagen, Becton Dickinson (BD), Roche Diagnostics and Abbott Diagnostics. Emerging players are Mesa Labs and GenMark Diagnostics (acquired by Roche). Direct peers are Cepheid (Danaher) and QuidelOrtho.

Does Rapidiagnostics have an API?

No public API is recorded for Rapidiagnostics.

What industry is Rapidiagnostics in?

Rapidiagnostics's product category is Diagnostic Testing. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales